Sompraz%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

# Sompraz HP ## Overview Sompraz HP is a fixed-dose combination product containing pantoprazole, amoxicillin, and clarithromycin. It is a proton pump inhibitor (PPI) and two antibiotics used for the eradication of *Helicobacter pylori* (*H. pylori*) infection. ## Primary Indications * Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease. ## Adult Dosing * The standard dose is one Sachet HP (containing pantoprazole 40 mg, amoxicillin 1000 mg, and clarithromycin 500 mg) taken twice daily for 7 days. * Administer one sachet in the morning and one sachet in the evening, typically before breakfast and before the evening meal, respectively. * The contents of the sachet should be dissolved in a suitable amount of water (e.g., 50-100 mL) and consumed immediately. ## Pediatric Dosing * Sompraz HP is not typically recommended for pediatric patients due to lack of established dosing and potential for adverse effects. Specific pediatric regimens for *H. pylori* eradication should be determined by a specialist. ## Dose Adjustments * **Renal Impairment:** No specific dose adjustment is recommended for pantoprazole, amoxicillin, or clarithromycin in mild to moderate renal impairment. In severe renal impairment, caution may be warranted, especially for amoxicillin, with potential for dose reduction. Consult prescribing information for specific guidance. * **Hepatic Impairment:** No dose adjustment is required for pantoprazole in mild to moderate hepatic impairment. Caution is advised in severe hepatic impairment. Clarithromycin dose adjustment is recommended in moderate to severe hepatic impairment. Amoxicillin generally does not require dose adjustment. Consult prescribing information for specific guidance. ## Contraindications * Hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation. * History of severe hypersensitivity to penicillins or cephalosporins. * History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use. * Concomitant use with cisapride, ergot alkaloids, midazolam, or pimozide. * Severe renal impairment (especially for amoxicillin). * Electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia) for pantoprazole. ## Adverse Effects * **Common:** Diarrhea, nausea, abdominal pain, headache, dysgeusia (altered taste), rash. * **Serious:** *Clostridium difficile*-associated diarrhea, severe allergic reactions (anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, liver dysfunction, QT prolongation (clarithromycin), fungal superinfections, *H. pylori* resistance. ## Key Drug Interactions * **Pantoprazole:** May decrease the absorption of drugs that require acidic gastric pH (e.g., ketoconazole, itraconazole, certain antiretrovirals). May increase levels of drugs metabolized by CYP2C19 (e.g., clopidogrel). * **Amoxicillin:** May decrease the efficacy of oral contraceptives. Probenecid may increase amoxicillin levels. * **Clarithromycin:** Strong CYP3A4 inhibitor. May increase levels of numerous drugs, including statins (risk of myopathy), colchicine (risk of toxicity), warfarin, calcium channel blockers, and certain immunosuppressants (e.g., cyclosporine, tacrolimus). May interact with other QT-prolonging agents. ## Monitoring * Assess for signs and symptoms of *H. pylori* eradication post-treatment (e.g., urea breath test, stool antigen test). * Monitor for adverse effects, particularly diarrhea (potential for *C. difficile*), rash, and allergic reactions. * Monitor liver function tests, especially with clarithromycin. * Monitor electrolytes (magnesium, potassium) with prolonged pantoprazole use. ## Clinical Pearls * Ensure the patient is not allergic to penicillin. * Advise patients to take the medication exactly as prescribed for the full duration to maximize eradication rates and minimize resistance. * Separation of administration of amoxicillin and clarithromycin from acid-reducing agents may not be necessary when used in a fixed-dose combination for *H. pylori* therapy, but individual components' interactions should still be considered. * Patients with peptic ulcer disease should continue therapy for the ulcer itself if indicated after *H. pylori* eradication. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete details before making treatment decisions. Local protocols may dictate specific dosing or management strategies.